Xalud Therapeutics is a biotechnology company developing a non-viral gene therapy platform to treat pathologic inflammation through immune modulation. The company is harnessing the power of interleukin-10 (IL-10), a potent cytokine that acts as a master regulator for multiple inflammatory pathways, to address the root cause of inflammation and subsequently restore homeostasis in the immune system. Xalud’s lead product candidate, XT-150, is a locally injectable plasmid DNA gene therapy expressing IL-10v, a proprietary modified variant of IL-10, that addresses pathologic inflammation and pain.
OUR
MISSION
Chronic inflammation is a hallmark of numerous serious diseases, including musculoskeletal, central nervous system, ophthalmic and dermal conditions. At Xalud Therapeutics, we strive to alleviate the high disease burden of chronic inflammation for millions of patients by harnessing the power of interleukin-10 (IL-10) and expanding the potential of gene therapy. Our desire to relieve the profound impact of chronic inflammation that patients experience is the driving force that motivates us every day.
Read More >
Chronic inflammation is a hallmark of numerous serious diseases, including musculoskeletal, central nervous system, ophthalmic and dermal conditions. At Xalud Therapeutics, we strive to alleviate the high disease burden of chronic inflammation for millions of patients by harnessing the power of interleukin-10 (IL-10) and expanding the potential of gene therapy. Our desire to relieve the profound impact of chronic inflammation that patients experience is the driving force that motivates us every day.
Read More >
OUR
SCIENCE
To accomplish our mission, we are advancing efforts in neuropathic and osteoarthritic pain, and we are working to transform the treatment of chronic inflammatory diseases with a novel non-viral gene therapy. Our lead product candidate, XT-150, targets a master regulator of the immune system, interleukin-10 (IL-10), that dampens inflammation to restore tissue homeostasis.
Read More >
To accomplish our mission, we are advancing efforts in neuropathic and osteoarthritic pain, and we are working to transform the treatment of chronic inflammatory diseases with a novel non-viral gene therapy. Our lead product candidate, XT-150, targets a master regulator of the immune system, interleukin-10 (IL-10), that dampens inflammation to restore tissue homeostasis.
Read More >
OUR
PIPELINE
Chronic inflammation spans countless disease areas and impacts over 300 million patients across the world. Chronic inflammatory conditions have a profound impact on health and quality of life through pain, loss of strength and function, and damage to multiple organ systems. With leading efforts in neuropathic and osteoarthritic pain, Xalud’s XT-150 is being studied in multiple chronic inflammatory diseases.
Read More >
Chronic inflammation spans countless disease areas and impacts over 300 million patients across the world. Chronic inflammatory conditions have a profound impact on health and quality of life through pain, loss of strength and function, and damage to multiple organ systems. With leading efforts in neuropathic and osteoarthritic pain, Xalud’s XT-150 is being studied in multiple chronic inflammatory diseases.
Read More >
